Cordyceps militaris Treatment Preserves Renal Function in Type 2 Diabetic Nephropathy Mice.
Diabetic nephropathy is derived from long-term effects of high blood glucose on kidney function in type 2 diabetic patients. Several antidiabetic drugs and herbal medications have failed to prevent episodes of DN. Hence, this study aimed to further investigate the renal injury-reducing effect of antidiabetic CmNo1, a novel combination of powders of fruiting bodies and mycelia of Cordyceps militaris. After being administered with streptozotocin-nicotinamide and high-fat-diet, the diabetic nephropathy mouse model displayed elevated blood glucose and renal dysfunction markers including serum creatinine and kidney-to-body weight ratio. These elevated markers were significantly mitigated following 8 weeks CmNo1 treatment. Moreover, the chronic hyperglycemia-induced pathological alteration in renal tissue were also ameliorated. Besides, immunohistochemical study demonstrated a substantial reduction in elevated levels of carboxymethyl lysine, an advanced glycation end product. Elevated collagenous deposition in DN group was also attenuated through CmNo1 administration. Moreover, the enhanced levels of transforming growth factor-β1, a fibrosis-inducing protein in glomerulus were also markedly dampened. Furthermore, auxiliary risk factors in DN like serum triglycerides and cholesterol were found to be increased but were decreased by CmNo1 treatment. Conclusively, the results suggests that CmNo1 exhibit potent and efficacious renoprotective action against hyperglycemia-induced DN.
Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan.|Stem Cell Research Center, Taipei Medical University, Taipei, Taiwan.
Sung-Hsun
SH
Yu
Stem Cell Research Center, Taipei Medical University, Taipei, Taiwan.|Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.
Navneet Kumar
NK
Dubey
Stem Cell Research Center, Taipei Medical University, Taipei, Taiwan.
Wei-Shan
WS
Li
Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.|Department of Urology, Taipei Medical University Hospital, Taipei, Taiwan.|Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Ming-Che
MC
Liu
Division of Urology, Department of Surgery, Cathay General Hospital, New Taipei City, Taiwan.|Graduate Institute of Basic Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
Han-Sun
HS
Chiang
Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan.|Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Sy-Jye
SJ
Leu
Department of Family Medicine, Taipei Medical University, Wan Fang Hospital, Taipei, Taiwan.
Ying-Hua
YH
Shieh
Cosmetic Clinic Group, Taipei, Taiwan.
Feng-Chou
FC
Tsai
Stem Cell Research Center, Taipei Medical University, Taipei, Taiwan.|Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.|Graduate Institute of Basic Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
Win-Ping
WP
Deng
D000818:Animals; D001688:Biological Products / Q000737:chemistry / Q000627:therapeutic use*; D003094:Collagen / Q000032:analysis; D032661:Cordyceps / Q000737:chemistry*; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D003928:Diabetic Nephropathies / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D048690:Fruiting Bodies, Fungal / Q000737:chemistry; D017127:Glycation End Products, Advanced / Q000032:analysis; D006003:Glycogen / Q000032:analysis; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D007677:Kidney Function Tests; D051379:Mice; D008810:Mice, Inbred C57BL; D025282:Mycelium / Q000737:chemistry; D013311:Streptozocin; D053773:Transforming Growth Factor beta1 / Q000032:analysis
D001688:Biological Products; D017127:Glycation End Products, Advanced; D007004:Hypoglycemic Agents; D053773:Transforming Growth Factor beta1; D013311:Streptozocin; D006003:Glycogen; D003094:Collagen